Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Buy” from Analysts

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXGet Rating) have been given a consensus recommendation of “Buy” by the nine brokerages that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $28.60.

A number of equities analysts have commented on SNDX shares. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 20th. HC Wainwright started coverage on shares of Syndax Pharmaceuticals in a report on Monday, April 11th. They issued a “buy” rating and a $31.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of Syndax Pharmaceuticals in a report on Tuesday, February 15th. They issued a “buy” rating and a $37.00 price objective on the stock. TheStreet upgraded shares of Syndax Pharmaceuticals from a “d” rating to a “c” rating in a report on Wednesday, March 9th. Finally, StockNews.com assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, March 31st. They issued a “hold” rating on the stock.

In other Syndax Pharmaceuticals news, insider Briggs Morrison sold 3,128 shares of the company’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $18.29, for a total value of $57,211.12. Following the completion of the transaction, the insider now owns 17,836 shares in the company, valued at approximately $326,220.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.30% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 2.9% in the first quarter. BlackRock Inc. now owns 3,798,150 shares of the company’s stock valued at $66,011,000 after acquiring an additional 108,256 shares in the last quarter. Frazier Management LLC lifted its stake in Syndax Pharmaceuticals by 133.3% during the fourth quarter. Frazier Management LLC now owns 2,772,062 shares of the company’s stock valued at $60,680,000 after purchasing an additional 1,583,927 shares during the last quarter. State Street Corp lifted its stake in Syndax Pharmaceuticals by 17.9% during the fourth quarter. State Street Corp now owns 2,480,204 shares of the company’s stock valued at $54,292,000 after purchasing an additional 376,757 shares during the last quarter. Wellington Management Group LLP lifted its stake in Syndax Pharmaceuticals by 2.5% during the third quarter. Wellington Management Group LLP now owns 1,676,859 shares of the company’s stock valued at $32,044,000 after purchasing an additional 40,928 shares during the last quarter. Finally, 683 Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 22.9% during the fourth quarter. 683 Capital Management LLC now owns 1,395,492 shares of the company’s stock valued at $30,547,000 after purchasing an additional 259,592 shares during the last quarter.

NASDAQ:SNDX opened at $13.95 on Friday. The company has a current ratio of 21.68, a quick ratio of 21.68 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $767.46 million, a price-to-earnings ratio of 32.44 and a beta of 1.53. The firm’s fifty day simple moving average is $17.11 and its 200 day simple moving average is $17.51. Syndax Pharmaceuticals has a twelve month low of $13.52 and a twelve month high of $22.71.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). Syndax Pharmaceuticals had a net margin of 17.84% and a return on equity of 9.49%. During the same quarter last year, the business posted ($0.54) EPS. On average, analysts predict that Syndax Pharmaceuticals will post -2.79 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile (Get Rating)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).

See Also

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.